Pfizer Drops as Drugmaker Predicts Little Sales Growth in 2026

Pfizer Inc. tumbled after it forecast little to no sales growth next year, a warning sign as the drugmaker works rebuild its pipeline of hit drugs with a series of pricey acquisitions.

Revenue in 2026 will be $59.5 billion to $62.5 billion, Pfizer said Tuesday in a statement. The midpoint of that range trails Wall Street’s $61.6 billion estimate and the $62 billion the company expects to report this year.